Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Intangibles (2016 - 2026)

Sunshine Biopharma filings provide 6 years of Intangibles readings, the most recent being $3.8 million for Q4 2025.

  • On a quarterly basis, Intangibles rose 25.64% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.8 million, a 25.64% increase, with the full-year FY2025 number at $3.8 million, up 25.64% from a year prior.
  • Intangibles hit $3.8 million in Q4 2025 for Sunshine Biopharma, up from $2.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $3.8 million in Q4 2025 to a low of $776856.0 in Q4 2022.
  • Median Intangibles over the past 4 years was $2.1 million (2024), compared with a mean of $2.2 million.
  • Biggest five-year swings in Intangibles: skyrocketed 135.89% in 2024 and later dropped 28.05% in 2025.
  • Sunshine Biopharma's Intangibles stood at $776856.0 in 2022, then surged by 85.91% to $1.4 million in 2023, then skyrocketed by 109.08% to $3.0 million in 2024, then rose by 25.64% to $3.8 million in 2025.
  • The last three reported values for Intangibles were $3.8 million (Q4 2025), $2.1 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.